# Japan expands approval of GSK’s Arexvy to at-risk adults aged 18–49

- Link: https://www.directorstalkinterviews.com/japan-expands-approval-of-gsk-s-arexvy-to-at-risk-adults-aged-18-49/4121251726
- Published: 2026-05-18T07:34:17+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l),
NYSE: GSK) has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)
has expanded the eligible population for _Arexvy_ (Respiratory Syncytial Virus vaccine,[
adjuvanted, recombinant]), to include adults aged 18 to 49 years at increased risk(
AIR) for RSV disease. GSK’s RSV vaccine was previously approved in Japan for the
prevention of RSV disease in all adults aged 60 years and older, and for adults 
aged 50-59 AIR for RSV disease. The prescribing information for _Arexvy_ has also
been updated to explicitly include immuno-compromised (IC) patients as an increased
risk group – helping clinicians to identify people who may benefit from RSV prevention.

**Sanjay Gurunathan,** **GSK Head of Vaccines and Infectious Diseases Research and
Development,** said:

“This expanded approval, the first covering all at-risk adults in Japan, can help
reduce potentially severe outcomes of RSV. It recognises the serious impact RSV 
can have for adults of any age living with chronic conditions such as cardiovascular
disease, chronic obstructive pulmonary disease and asthma, and it enables more people
to take a proactive approach to disease prevention.”

RSV is a common and contagious respiratory virus that can cause serious illness 
in adults, particularly those living with certain chronic conditions.^(6,[7],[8])
RSV infection can cause major adverse cardiovascular events (MACE) including heart
attack and stroke,^(4,[9],[10],[11],[12]) trigger flare-ups of chronic obstructive
pulmonary disease (COPD) and asthma and may result in severe illness, hospitalisation,
and even death.^(6) More than 42 million adults in Japan are aged 18-49^(1) and,
while often considered at low risk of RSV, many in this group live with underlying
chronic conditions.^(2)

The approval was supported by data from a Phase IIIb trial (NCT06389487) demonstrating
a non-inferior immune response in adults aged 18 to 49 years AIR  for RSV disease
compared to adults aged 60 years and above.^([13]) Vaccine efficacy was demonstrated
in the earlier Phase III trial (NCT04886596).^([14]) The safety profile was consistent
with findings from the broader Phase III programme that supported the initial approval
with the most common adverse events being injection site pain, myalgia, fatigue,
arthralgia and headache, which were largely transient and mild to moderate in intensity.
^(13) The update to the prescribing information to include IC patients, accepted
by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), was supported by data
from a Phase IIb trial (NCT05921903).^([15])

GSK continues to advance regulatory submissions for its RSV vaccine across multiple
geographies to expand availability and support disease prevention.

**About GSK’s RSV vaccine**

Respiratory Syncytial Virus vaccine (adjuvanted) contains recombinant RSV glycoprotein
F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined 
with GSK’s proprietary AS01_(E) adjuvant before administration.

The use of this vaccine should be in accordance with official recommendations. As
with any vaccine, a protective immune response may not be elicited in all vaccinees.

The vaccine has been approved for the prevention of RSV-LRTD in individuals 60 years
of age and older in 70 countries. In addition, it is approved for use in individuals
aged 50-59 years who are at increased risk due to certain underlying medical conditions
in more than 60 countries. In the US it is also approved in adults aged 18-49 years
at increased risk, and in the European Economic Area for all adults aged 18 years
and older.^([16],[17])

The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed
from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark
of SaponiQx Inc., a subsidiary of Agenus.

Please refer to the updated Product Information (PI) for precautions concerning 
indications, dosage and administration and safety information in Japan at this link:
Japan Pharmaceuticals and Medical Devices Agency^([18])

**References:**

[1] E-Stat: Statistics of Japan. Available at: https://www.e-stat.go.jp/en/stat-
search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=1&tclass1
=000001011678&tclass2val=0. Last accessed: May 2026.

[2] Saito Y, et al. Prevalence of multimorbidity and its associations with hospitalisation
or death in Japan 2014-2019: a retrospective cohort study using nationwide medical
claims data in the middle-aged generation. BMJ Open. 2023;13(5):e063216.

[3] Njue A, et al. Systematic Literature Review of Risk Factors for Poor Outcomes
Among Adults With Respiratory Syncytial Virus Infection in High-Income Countries.
Open Forum Infectious Diseases (2023) 10(11): ofad513.

[4] Montiel J, et al. The risk of cardiac disease events after respiratory syncytial
virus disease: a systematic literature review and meta-analysis. European Respiratory
Review (2026); 35:250160.

[5] Penders Y, et al. Burden of Respiratory Syncytial Virus Disease in Adults with
Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review.
Current Allergy and Asthma Reports. 2025;25:14.

[6] Falsey AR, et al. Respiratory syncytial virus infection in elderly and high-
risk adults. New Engl J Med. 2005;352:1749-1759.

[7] National Institute of Allergy and Infectious Diseases, Respiratory Syncytial
Virus (RSV). Available at: https://www.niaid.nih.gov/diseases-conditions/respiratory-
syncytial-virus-rsv. Last accessed: May 2026.

[8] Branche AR; et al. Incidence of Respiratory Syncytial Virus Infection Among 
Hospitalized Adults, 2017-2020. Clin Infect Dis.2022;74;1004-1011.

[9] Hviid A, et al. Cardiovascular Events 1 Year After Respiratory Syncytial Virus
Infection in Adults. JAMA Netw Open. 2025;8(12):e2547618.

[10] Liang C, et al. Risk of Cardiorespiratory Events Following Respiratory Syncytial
Virus-Related Hospitalization. JAMA Netw Open. 2026;9(2):e2556767

[11] Sudnik P, et al. Comprehensive Analysis of Cardiovascular Events and Risk Factors
in Patients Hospitalized With Respiratory Syncytial Virus. Clin Infect Dis. 2026
Feb 25;82(2):e396-e403.

[12] Woodruff R, et al. Acute Cardiac Events in Hospitalized Older Adults With Respiratory
Syncytial Virus Infection. JAMA Intern Med. 2024;184(6):602-611.

[13] Clinicaltrials.gov. A Study on the Immune Response and Safety of Vaccine Against
Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased
Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years 
of Age and Above. Available at: https://clinicaltrials.gov/study/NCT06389487. Last
accessed: May 2026.

[14] Clinicaltrials.gov. Efficacy Study of GSK’s Investigational Respiratory Syncytial
Virus (RSV) Vaccine in Adults Aged 60 Years and Above. Available at: https://clinicaltrials.
gov/study/NCT04886596. Last accessed: May 2026.

[15] Clinicaltrials.gov. A Study on the Immune Response and Safety of an RSV Vaccine
When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract
Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023).
Available at: https://clinicaltrials.gov/study/NCT05921903. Last accessed: May 2026.

[16] GSK. Arexvy. US Prescribing Information. Available at: https://gskpro.com/content/
dam/global/hcpportal/en_US/Prescribing_Information/Arexvy/pdf/AREXVY.PDF. Last accessed:
May 2026.

[17] EMA. Arexvy. Summary of Product Characteristics. Available at: https://www.
ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_en.
pdf. Last accessed: May 2026.

[18] Japan Pharmaceuticals and Medical Devices Agency. Pharmaceuticals Information.
Available at: https://www.pmda.go.jp/PmdaSearch/iyakuSearch/ Last accessed May 2026

Share on:
